Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors

  • Cancer
Trial Status:

Recruiting

This trial runs in
Countries
  • Australia
  • Canada
  • France
  • Japan
  • South Korea
  • Spain
  • United States
Trial Identifier:

NCT02794571 2016-000944-33 GO30103

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of tiragolumab alone or in combination with atezolizumab and/or other anti-cancer therapies in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.

      Genentech, Inc. Sponsor
      Phase 1 Phase
      NCT02794571 , GO30103 , 2016-000944-33 Trial Identifier
      Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Etoposide, Capecitabine, Bevacizumab, Pembrolizumab Treatments
      Advanced/Metastatic Tumors Condition
      Official Title

      A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Patients With Locally Advanced or Metastatic Tumors

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Adults 18 years of age or older
      • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
      • Life expectancy at least 12 weeks
      • Adequate hematologic and end organ function
      • Histologic documentation of locally advanced, recurrent, or metastatic incurable malignancy that has progressed after at least one available standard therapy; or for which standard therapy has proven ineffective, intolerable, or considered inappropriate; or for which a clinical trial of an investigational agent is a recognized standard of care
      • Confirmed availability of representative tumor specimens
      • Measurable disease according to RECIST Version 1.1
      Exclusion Criteria
      • Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment
      • Malignancies other than disease under study within 5 years prior to Day 1 of Cycle 1
      • Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases
      • Leptomeningeal disease
      • History of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or evidence of active pneumonitis on Screening chest computed tomograph (CT) scan
      • History of autoimmune disease
      • Positive human immunodeficiency virus (HIV) test
      • Active hepatitis B or C, or tuberculosis
      • Severe infection within 4 weeks prior to randomization
      • Prior allogeneic bone marrow or solid organ transplant
      • Significant cardiovascular disease
      • Known clinically significant liver disease

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now